Table 2

The predictive value of baseline depression/anxiety for achievement of joint remission after 3 and 6 months treatment (logistic regression analyses)

MonthsDAS28ESR<2.6SDAI≤3.3CDAI≤2.8ACR/EULAR BooleanDAPSA≤4
OR (95% CI) for joint remission in patients with versus without baseline depression/anxiety according to the EQ-5D-3L criterion
3RA0.66 (0.49 to 0.90), p=0.008 (n=855)0.57 (0.39 to 0.83), p=0.003 (n=924)0.49 (0.34 to 0.70), p<0.001 (n=991)0.46 (0.30 to 0.71), p<0.001 (n=1017)0.58 (0.39 to 0.86), p=0.006 (n=924)
PsA0.74 (0.48 to 1.12), p=0.15 (n=416)0.59 (0.37 to 0.96), p=0.03 (n=455)0.50 (0.32 to 0.78), p=0.002 (n=522)0.51 (0.30 to 0.88), p=0.02 (n=533)0.54 (0.33 to 0.91), p=0.02 (n=455)
6RA0.48 (0.35 to 0.66), p<0.001 (n=715)0.45 (0.31 to 0.65), p<0.001 (n=788)0.46 (0.33 to 0.65), p<0.001 (n=880)0.44 (0.29 to 0.66), p<0.001 (n=886)0.37 (0.25 to 0.54), p<0.001 (n=797)
PsA0.92 (0.59 to 1.44), p=0.73 (n=371)0.70 (0.44 to 1.12), p=0.14 (n=426)0.69 (0.45 to 1.06), p=0.09 (n=488)0.61 (0.37 to 1.01), p=0.05 (n=492)0.69 (0.43 to 1.10), p=0.12 (n=428)
OR (95% CI) for joint remission in patients with versus without baseline depression/anxiety according to the SF-36MH≤56 criterion
3RA0.48 (0.31 to 0.73), p=0.001 (n=841)0.37 (0.20 to 0.67), p=0.001 (n=911)0.35 (0.19 to 0.61), p<0.001 (n=977)0.22 (0.09 to 0.50), p<0.001 (n=1003)0.15 (0.06 to 0.34), p<0.001 (n=924)
PsA0.59 (0.33 to 1.05), p=0.07 (n=414)0.36 (0.16 to 0.80), p=0.01 (n=453)0.49 (0.25 to 0.99), p=0.046 (n=520)0.59 (0.27 to 1.31), p=0.20 (n=530)0.37 (0.17 to 0.82), p=0.01 (n=463)
6RA0.33 (0.21 to 0.53), p<0.001 (n=709)0.28 (0.16 to 0.52), p<0.001 (n=782)0.30 (0.17 to 0.54), p<0.001 (n=874)0.30 (0.50 to 0.61), p=0.001 (n=878)0.25 (0.13 to 0.47), p<0.001 (n=791)
PsA0.78 (0.41 to 1.46), p=0.43 (n=368)0.40 (0.18 to 0.86), p=0.02 (n=423)0.41 (0.20 to 0.86), p=0.02 (n=485)0.65 (0.29 to 1.43), p=0.28 (n=488)0.43 (0.20 to 0.91), p=0.03 (n=424)
OR (95% CI) for joint remission in patients with versus without baseline depression/anxiety according to the SF-36MCS≤38 criterion
3RA0.67 (0.48 to 0.93), p=0.02 (n=819)0.44 (0.28 to 0.69), p<0.001 (n=890)0.40 (0.26 to 0.62), p<0.001 (n=954)0.26 (0.14 to 0.47), p<0.001 (n=979)0.33 (0.20 to 0.53), p<0.001 (n=903)
PsA0.60 (0.36 to 0.99), p=0.04 (n=403)0.35 (0.18 to 0.68), p=0.002 (n=443)0.44 (0.24 to 0.78), p=0.005 (n=505)0.43 (0.21 to 0.87), p=0.02 (n=517)0.39 (0.21 to 0.74), p=0.004 (n=454)
6RA0.40 (0.28 to 0.57), p<0.001 (n=693)0.40 (0.26 to 0.61), p<0.001 (n=765)0.39 (0.26 to 0.58), p<0.001 (n=854)0.45 (0.28 to 0.72), p=0.001 (n=859)0.30 (0.19 to 0.48), p<0.001 (n=774)
PsA0.76 (0.44 to 1.32), p=0.32 (n=356)0.39 (0.20 to 0.75), p=0.005 (n=411)0.43 (0.23 to 0.79), p=0.006 (n=471)0.55 (0.28 to 1.09), p=0.09 (n=474)0.40 (0.21 to 0.78), p=0.007 (n=412)
  • Analyses were adjusted for age, gender, disease duration and smoking.

  • CDAI, Clinical Disease Activity Index; DAPSA, Disease Activity Index for Psoriatic Arthritis; DAS28, 28-joint disease activity score; EQ-5D-3L, question five from the EuroQol-5D-3L questionnaire; PsA, psoriatic arthritis (n=728); RA, rheumatoid arthritis (n=1326); SDAI, Simplified Disease Activity Index; SF-36MH, Medical Outcomes Survey Short Form-36 Mental Health subscale; SF-36MCS, Medical Outcomes Survey Short Form-36 Mental Component Summary.